| [1] |
Fallone CA, Moss SF, Melfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics [J]. Gastroenterology, 2019, 157(1): 44-53.
|
| [2] |
Huttner A, Bielicki J, Clements MN, et al. Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage [J]. Clin Microbiol Infect, 2020, 26(7): 871-879.
|
| [3] |
Ghim JL, Chin MC, Jung J, et al. Pharmacokinetics and pharmacodynamics of tegoprazan co-administered with amoxicillin and clarithromycin in healthy subjects [J]. J Clin Pharmacol, 2021, 61(7): 913-922.
|
| [4] |
Thomas L, Le Beller C, Trenque T, et al. Amoxicillin-induced crystal nephropathy: a nationwide French pharmacovigilance databases study [J]. Br J Clin Pharmacol, 2020, 86(11): 2256-2265.
|
| [5] |
Ferrari B, Fogazzi GB, Garigali G, et al. Acute interstitial nephritis after amoxycillin with hematuria, red blood cell casts and hematuria-induced acute tubular injury [J]. Clin Nephrol, 2013, 80(2): 156-160.
|
| [6] |
Appel GB, Garvey G, Silva F, et al. Acute interstitial nephritis due to amoxicillin therapy [J]. Nephron, 1981, 27(6): 313-315.
|
| [7] |
Garnier AS, Dellamaggiore J, Brilland B, et al. High incidence of amoxicillin-induced crystal nephropathy in patients receiving high dose of intravenous amoxicillin [J]. J Clin Med, 2020, 9(7): 2022.
|
| [8] |
Vodovar D, Thomas L, Mongardon N, et al. Dramatic increase of amoxicillin-induced crystal nephropathy found in a cohort study of French pharmacovigilance centers [J]. Antimicrob Agents Chemother, 2018, 62(3): e01630-17.
|
| [9] |
国家药品监督管理局. 药品不良反应信息通报(第47期)警惕超剂量使用注射用阿莫西林钠可能增加肾损害发生风险[EB/OL]. 2012:
URL
|
| [10] |
Bright DA, Gaupp FB, Becker LJ, et al. Amoxicillin overdose with gross hematuria [J]. West J Med, 1989, 150(6): 698-699.
|
| [11] |
Jones DP, Gaber L, Nilsson GR, et al. Acute renal failure following amoxicillin overdose [J]. Clin Pediatr (Phila), 1993, 32(12): 735-739.
|
| [12] |
Belko J, Urueta G, Emre U. Amoxicillin overdose manifested by hematuria and acute renal failure [J]. Pediatr Infect Dis J, 1995, 14(10): 917-919.
|
| [13] |
Geller RJ, Chevalier RL, Spyker DA. Acute amoxicillin nephrotoxicity following an overdose [J]. J Toxicol Clin Toxicol, 1986, 24(2): 175-182.
|
| [14] |
Schellie SF, Groshong T. Acute interstitial nephritis following amoxicillin overdose [J]. Mo Med, 1999, 96(6): 209-211.
|
| [15] |
Lee SW, Choi Y, Jang K, et al. Multiple-dose pharmacokinetics and safety of amoxicillin/clavulanate in healthy elderly subjects [J]. Int J Clin Pharmacol Ther, 2020, 58(11): 634-641.
|
| [16] |
许瑞凌，吴国贤. 阿莫西林-舒巴坦致老年患者急性间质性肾炎2例[J]. 药物不良反应杂志，2010, 12(6): 440-441.
|
| [17] |
Valluri A, Hetherington L, Mcquarrie E, et al. Acute tubulointerstitial nephritis in Scotland [J]. QJM, 2015, 108(7): 527-532.
|
| [18] |
Mulay SR, Anders HJ. Crystal nephropathies: mechanisms of crystal-induced kidney injury [J]. Nat Rev Nephrol, 2017, 13(4): 226-240.
|
| [19] |
Liu Z, Xiao Y, Chen W, et al. Calcium phosphate nanoparticles primarily induce cell necrosis through lysosomal rupture: the origination of material cytotoxicity [J]. J Mater Chem B, 2014, 2(22): 3480-3489.
|
| [20] |
付亮，唐外姣，吴海雄. 超剂量用药致尿沉渣中出现阿莫西林-克拉维酸钾结晶1例[J]. 检验医学，2020, 35(1): 92-94.
|
| [21] |
张磊，许建明．幽门螺杆菌感染处理共识解读及实施意见[J]．安徽医学，2016, 37(11): 1319-1323.
|
| [22] |
Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy issuperior to standard first-line or rescue therapy forHelicobacter pyloriinfection [J]. Clin Gastroenterol Hepatol, 2015, 13(5): 895-905.
|
| [23] |
Sahara S, Sugimoto M, Ichikawa H, et al. Efficacy of reduced dosage of amoxicillin in an eradication therapy for Helicobacter pylori infection in patients on hemodialysis: a randomized controlled trial [J]. Digestion, 2018, 97(2): 163-169.
|
| [24] |
Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori [J]. Clin Pharmacol Ther, 2007, 81(4): 521-528.
|
| [25] |
Furuta T, Sugimoto M, Yamade M, et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy [J]. J ClinPharmacol, 2014, 54(3): 258-266.
|
| [26] |
Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori [J]. Am J Gastroenterol, 2019, 114(3): 437-445.
|
| [27] |
Yu L, Luo L, Long X, et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial [J]. Helicobacter, 2019, 24(4): e12596.
|
| [28] |
Tai WC, Liang CM, Kuo CM, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial [J]. J Antimicrob Chemother, 2019, 74(6): 1718-1724.
|
| [29] |
Seyyed Majidi M, Sanjari Pirayvatlou P, Rajabikashani M, et al. Comparison of Helicobacter pylori eradication regimens in patients with end stage renal disease [J]. Gastroenterol Hepatol Bed Bench, 2018, 11(1): 15-19.
|
| [30] |
Gaber DA, Alhawas HS, Alfadhel FA, et al. Mini-tablets versus nanoparticles for controlling the release of amoxicillin: in vitro/in vivo study [J]. Drug Des Devel Ther, 2020, 14: 5405-5418.
|